MeiraGTx (NASDAQ:MGTX) & Biomea Fusion (NASDAQ:BMEA) Critical Analysis

Biomea Fusion (NASDAQ:BMEA) and MeiraGTx (NASDAQ:MGTX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.

Volatility and Risk

Biomea Fusion has a beta of -0.28, indicating that its share price is 128% less volatile than the S&P 500. Comparatively, MeiraGTx has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500.

Profitability

This table compares Biomea Fusion and MeiraGTx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biomea Fusion	N/A	-253.73%	-97.91%
MeiraGTx	19.87%	283.85%	29.39%

Analyst Recommendations

This is a breakdown of recent recommendations for Biomea Fusion and MeiraGTx, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomea Fusion	1	0	5	0	2.67
MeiraGTx	1	0	5	2	3.00

Biomea Fusion currently has a consensus price target of $8.20, indicating a potential upside of 512.40%. MeiraGTx has a consensus price target of $26.17, indicating a potential upside of 85.19%. Given Biomea Fusion’s higher probable upside, equities analysts plainly believe Biomea Fusion is more favorable than MeiraGTx.

Institutional and Insider Ownership

96.7% of Biomea Fusion shares are held by institutional investors. Comparatively, 67.5% of MeiraGTx shares are held by institutional investors. 10.6% of Biomea Fusion shares are held by insiders. Comparatively, 7.4% of MeiraGTx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Biomea Fusion and MeiraGTx”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomea Fusion	N/A	N/A	-$61.80 million	($0.29)	-4.62
MeiraGTx	$397.50 million	3.41	-$114.20 million	$0.71	19.90

Biomea Fusion has higher earnings, but lower revenue than MeiraGTx. Biomea Fusion is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Summary

MeiraGTx beats Biomea Fusion on 9 of the 13 factors compared between the two stocks.

About Biomea Fusion

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

About MeiraGTx

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.